SinoMab BioScience Announces Successful Dosing of First Cohort in Bridging Study of Subcutaneous SM17 in China

Reuters10-14

SinoMab BioScience Announces Successful Dosing of First Cohort in Bridging Study of Subcutaneous SM17 in China

SinoMab BioScience Limited announced the successful dosing of the first cohort of healthy subjects with the subcutaneous formulation of SM17 in a bridging study in China. As of the announcement date, all participants tolerated the treatment well, and no adverse events, including injection site reactions, were reported. The study aims to assess the safety, tolerability, and pharmacokinetic profiles of SM17 administered subcutaneously. Preclinical and Phase 1 data on SM17's safety and pharmacokinetics have been previously published in peer-reviewed journals. The results of this bridging study have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575967242?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575967242","market":"nz","top_or_hot":-1,"title":"SinoMab BioScience Announces Successful Dosing of First Cohort in Bridging Study of Subcutaneous SM17 in China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SinoMab BioScience Announces Successful Dosing of First Cohort in Bridging Study of Subcutaneous SM17 in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SinoMab BioScience Limited announced the successful dosing of the first cohort of healthy subjects with the subcutaneous formulation of SM17 in a bridging study in China. As of the announcement date, all participants tolerated the treatment well, and no adverse events, including injection site reactions, were reported. The study aims to assess the safety, tolerability, and pharmacokinetic profiles of SM17 administered subcutaneously. Preclinical and Phase 1 data on SM17's safety and pharmacokinetics have been previously published in peer-reviewed journals. The results of this bridging study have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SinoMab BioScience Announces Successful Dosing of First Cohort in Bridging Study of Subcutaneous SM17 in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinoMab BioScience Announces Successful Dosing of First Cohort in Bridging Study of Subcutaneous SM17 in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 18:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SinoMab BioScience Announces Successful Dosing of First Cohort in Bridging Study of Subcutaneous SM17 in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SinoMab BioScience Limited announced the successful dosing of the first cohort of healthy subjects with the subcutaneous formulation of SM17 in a bridging study in China. As of the announcement date, all participants tolerated the treatment well, and no adverse events, including injection site reactions, were reported. The study aims to assess the safety, tolerability, and pharmacokinetic profiles of SM17 administered subcutaneously. Preclinical and Phase 1 data on SM17's safety and pharmacokinetics have been previously published in peer-reviewed journals. The results of this bridging study have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL1F51HG:1","article_id":"2575967242","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575967242","pubTimestamp":1760437811,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SinoMab BioScience Limited announced the successful dosing of the first cohort of healthy subjects with the subcutaneous formulation of SM17 in a bridging study in China. As of the announcement date, all participants tolerated the treatment well, and no adverse events, including injection site reactions, were reported. The study aims to assess the safety, tolerability, and pharmacokinetic profiles of SM17 administered subcutaneously. Preclinical and Phase 1 data on SM17's safety and pharmacokinetics have been previously published in peer-reviewed journals. The results of this bridging study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","03681":"中国抗体-B"},"translate_title":"SinoMab BioScience宣布中国皮下SM17桥接研究首个队列成功给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03681":0.9},"content_text":"SinoMab BioScience Announces Successful Dosing of First Cohort in Bridging Study of Subcutaneous SM17 in China\n    \n\n        SinoMab BioScience Limited announced the successful dosing of the first cohort of healthy subjects with the subcutaneous formulation of SM17 in a bridging study in China. As of the announcement date, all participants tolerated the treatment well, and no adverse events, including injection site reactions, were reported. The study aims to assess the safety, tolerability, and pharmacokinetic profiles of SM17 administered subcutaneously. Preclinical and Phase 1 data on SM17's safety and pharmacokinetics have been previously published in peer-reviewed journals. The results of this bridging study have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575967242","isCrawlerRequest":true}